AU2005292033A1 - Treatment method - Google Patents

Treatment method Download PDF

Info

Publication number
AU2005292033A1
AU2005292033A1 AU2005292033A AU2005292033A AU2005292033A1 AU 2005292033 A1 AU2005292033 A1 AU 2005292033A1 AU 2005292033 A AU2005292033 A AU 2005292033A AU 2005292033 A AU2005292033 A AU 2005292033A AU 2005292033 A1 AU2005292033 A1 AU 2005292033A1
Authority
AU
Australia
Prior art keywords
mtor inhibitor
administered
aml
therapy
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005292033A
Other languages
English (en)
Inventor
Camille L. Bedrosian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Pharmaceuticals Inc
Original Assignee
Ariad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharmaceuticals Inc filed Critical Ariad Pharmaceuticals Inc
Publication of AU2005292033A1 publication Critical patent/AU2005292033A1/en
Assigned to ARIAD PHARMACEUTICALS, INC. reassignment ARIAD PHARMACEUTICALS, INC. Request for Assignment Assignors: ARIAD GENE THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2005292033A 2004-09-30 2005-09-30 Treatment method Abandoned AU2005292033A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61548504P 2004-09-30 2004-09-30
US60/615,485 2004-09-30
PCT/US2005/035047 WO2006039414A2 (en) 2004-09-30 2005-09-30 Treatment method

Publications (1)

Publication Number Publication Date
AU2005292033A1 true AU2005292033A1 (en) 2006-04-13

Family

ID=36143059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005292033A Abandoned AU2005292033A1 (en) 2004-09-30 2005-09-30 Treatment method

Country Status (7)

Country Link
US (1) US20080081053A1 (cg-RX-API-DMAC7.html)
EP (1) EP1809276A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008514721A (cg-RX-API-DMAC7.html)
AU (1) AU2005292033A1 (cg-RX-API-DMAC7.html)
CA (1) CA2581372A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007003790A (cg-RX-API-DMAC7.html)
WO (1) WO2006039414A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
EP2662082A1 (en) * 2005-11-14 2013-11-13 Ariad Pharmaceuticals, Incorporated Administration of mTOR inhibitors
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
US20090311249A1 (en) * 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
US20080161335A1 (en) * 2006-11-14 2008-07-03 Vladyka Ronald S Oral formulations
TWI597061B (zh) * 2013-02-20 2017-09-01 國鼎生物科技股份有限公司 治療白血病之方法及組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
EP1478648B1 (en) * 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
US7026330B2 (en) * 2002-05-30 2006-04-11 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
AU2003248813A1 (en) * 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
EP1809276A4 (en) 2009-06-17
WO2006039414A3 (en) 2006-07-06
MX2007003790A (es) 2007-05-24
JP2008514721A (ja) 2008-05-08
US20080081053A1 (en) 2008-04-03
WO2006039414A2 (en) 2006-04-13
CA2581372A1 (en) 2006-04-13
EP1809276A2 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
Slevin et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
EP3821887B1 (en) Use of mitoxantrone liposome for treating non-hodgkin's lymphoma
JP6294459B2 (ja) 骨髄性白血病の処置方法
Halle et al. Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients
US20080081053A1 (en) Treatment Method
Gelmon et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
Lee et al. Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia
Liu et al. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs
WO2015153820A1 (en) Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
AU2013208649B2 (en) Combination therapy for the treatment of cancer
Jara-Sánchez et al. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
JP4020256B2 (ja) 前立腺癌の局所治療剤
CN1901906A (zh) 治疗套细胞淋巴瘤的cci－779
AU2011202637A1 (en) Composition and methods for treating myelodysplastic syndrome
JP2002205945A (ja) 抗癌剤の併用投与方法及び併用可能な抗癌剤
JP2025516925A (ja) 再発がんを前治療する方法
KR20050116166A (ko) 이리노테칸의 저항성 유방암 치료용 용도
HK40044845B (en) Use of mitoxantrone liposome for treating non-hodgkin’s lymphoma
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
TW201306831A (zh) 用於治療骨髓發育不良症候群的組成物及方法
Schindler Immunological effects of amphotericin B desoxycholate and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice
CN108478581A (zh) 防治运动病、梅尼埃病的药物及托伐普坦的医药用途
WO2013019222A1 (en) Compositions and methods for treating myelodysplastic syndrome

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ARIAD PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): ARIAD GENE THERAPEUTICS, INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted